SecBot SecBot

ARVN drug pipeline

ARVINAS, INC. · 5 rated drugs
$6.77
−0.7% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±7.6%
1-day, median of 6 events
IV rank
No data
No current options data
Rated drugs
5
1 bearish · 4 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketAt least several years away. The drug is in Phase 1 dose escalation (estimated primary completion March 2028), requiring Phase 2/3 trials and regulatory review before any potential approval.

ARV-393 zaloblideg Updated Nov 3

What to watch

The next hard catalyst is the initial Phase 1 monotherapy dose escalation data for ARV-393, submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026). Positive safety and early efficacy signals could re-rate the stock from near its 52-week low; any safety or tolerability concerns would be a setback for the BCL6 degrader program. A second data readout is expected in mid-2027.

Bull case
  • ARV-393 is a first-in-class oral PROTAC BCL6 degrader targeting an undruggable oncogenic driver in non-Hodgkin lymphoma, with strong preclinical data showing tumor regressions across multiple DLBCL models. Initial Phase 1 monotherapy data will be presented at ASH (Dec 12-15, 2026), a major medical conference, providing the first clinical proof-of-concept. Arvinas has $558.9M in cash (runway into H2 2028) and a diversified pipeline including the approved VEPPANU (vepdegestrant), reducing single-asset risk. Analyst consensus is positive: 13 Buy/Strong Buy vs 1 Sell, with a mean price target of $14.54 (93% upside from $7.52).
Bear case
  • ARV-393 is still in Phase 1 dose escalation with no clinical efficacy data yet; early-stage readouts often fail to translate. Competitor BMS-986458 (Bristol Myers Squibb) is also a BCL6 degrader in Phase 1/2, potentially beating ARV-393 to market with deeper pockets. Arvinas stock trades near its 52-week low ($6.74) and fell ~5.7% on Q3 earnings day, reflecting limited market enthusiasm for the early pipeline. The company has an approved product (vepdegestrant) but out-licensed it to Rigel, capping upside from that asset.
● neutral
Impact
PhasePhase 1
Time to marketARV-027 is in Phase 1; assuming successful development, a potential approval is likely several years away (Phase 3 and regulatory review would follow Phase 1/2).

ARV-027 Updated Nov 3

What to watch

The next catalyst for ARV-027 is initial Phase 1 healthy-volunteer data, expected in the first half of 2027. Positive proof-of-mechanism (muscle androgen-receptor degradation) would validate the PROTAC approach in SBMA and could lift the stock; negative safety or PK results would be a setback for the program. The stock also has nearer-term catalysts in ARV-393 (ASH data December 2026) and ARV-102 updates, so ARV-027 is not the only binary event on the horizon.

Bull case
  • ARV-027 is a first-in-class oral PROTAC degrader targeting the root cause of SBMA (mutant androgen receptor protein), with no approved disease-modifying therapy currently on the market for this rare neuromuscular disease.
  • Preclinical data showed ARV-027 induced potent degradation of polyQ-AR in vitro and in vivo, rescued premature lethality, and improved muscle function in SBMA animal models, providing a strong mechanistic rationale.
  • Arvinas has $558.9M in cash with runway into H2 2028, sufficient to fund ARV-027 through Phase 1 and into later-stage trials without near-term financing risk.
Bear case
  • ARV-027 is still in Phase 1 with no human efficacy data yet; initial healthy-volunteer data (H1 2027) is early-stage and may not demonstrate sufficient target engagement or safety to justify advancing to patient dosing.
  • A competitor, AnnJi Pharmaceutical's AJ201 (rosolutamide), has already advanced to Phase 3 for SBMA, putting ARV-027 significantly behind in the race for a disease-modifying therapy.
  • Arvinas stock trades near its 52-week low of $6.74, reflecting market skepticism about the broader pipeline. The company reported a GAAP net loss of $53.9M in Q3 2026, and while it has $558.9M cash, the burn rate is substantial.
● neutral
Impact
PhasePhase 1
Time to marketYears away. ARV-102 is in Phase 1 for Parkinson's disease. The PSP Phase 1b trial is expected to begin in 2027 in the EU/UK. Even if successful, Phase 2 and Phase 3 trials would be needed before any regulatory filing, likely several years away.

ARV-102 Updated Nov 3

What to watch

Watch for the EU CTA submission for the PSP Phase 1b trial (targeted Q4 2026) and any resolution of the US clinical hold. Positive regulatory progress could lift the stock, while further delays or negative safety signals from the ongoing Parkinson's Phase 1 would pressure shares. The stock already trades near its 52-week low ($6.74) with a $558.9M cash runway into H2 2028.

Bull case
  • Phase 1 data showed >50% LRRK2 degradation in CSF of Parkinson's patients after 28 days, with good tolerability and brain penetration, validating the PROTAC approach in the CNS.
  • Oculomotor and biomarker data presented at MDS 2026 (October 2026) showed improvements in eye-movement measures correlated with biomarker changes, suggesting target engagement and potential clinical benefit.
  • Arvinas has $558.9M in cash with runway into H2 2028, sufficient to fund multiple pipeline programs including ARV-102 through several catalysts.
Bear case
  • The planned US Phase 1b PSP trial is on FDA clinical hold, with no disclosed resolution timeline, creating regulatory uncertainty.
  • The LRRK2 target class suffered a major setback: Biogen/Denali's BIIB122 failed a Phase 2b study and was discontinued for idiopathic Parkinson's, raising questions about the mechanism.
  • ARV-102 is still in Phase 1 with no pivotal or registrational trial data expected for years; the next catalyst is a regulatory filing (CTA), not a binary efficacy readout.
● neutral
Impact
PhasePhase 1/2
Time to marketAt least several years. The drug is in Phase 1/2 dose-escalation with first patient dosed in September 2026. Initial clinical data is expected in H2 2027. If successful, a registrational trial and FDA review would follow, likely pushing potential approval into the 2030s.

ARV-6723 Updated Nov 3

What to watch

ARV-6723 is in very early clinical development with no binary catalyst in the next 12 months. Watch for the SITC 2026 preclinical poster (Nov 4-8) and any early safety signals from the Phase 1 dose-escalation cohort. Initial clinical data is not expected until H2 2027. The drug is one of several pipeline assets at Arvinas, so its individual impact on the stock is limited in the near term.

Bull case
  • Preclinical data showed ARV-6723 as a monotherapy demonstrated superior antitumor activity compared to anti-PD-1 antibodies and an investigational HPK1 inhibitor across multiple solid tumor models, including checkpoint-resistant models.
  • ARV-6723 is the first HPK1 PROTAC degrader to enter clinical trials in the United States, and its degradation mechanism may offer advantages over traditional kinase inhibitors by also disrupting HPK1's scaffolding functions.
  • Arvinas has a strong cash position of $558.9M with runway into H2 2028, sufficient to fund multiple clinical programs including ARV-6723 through initial data readouts.
Bear case
  • ARV-6723 is in a Phase 1/2 first-in-human trial with no clinical efficacy or safety data yet; early-stage oncology drugs have a high failure rate.
  • HPK1 is a competitive target with several small-molecule inhibitors already in clinical trials from other developers, creating a crowded field.
  • The stock trades at $7.09, down ~5.7% on Q3 earnings day, and has a 52-week low of $6.74, indicating persistent selling pressure.
▼ bearish
Impact
PhasePhase 1/2
Time to marketARV-806 is in Phase 1 dose escalation with no internal Phase 2/3 plans; the company is seeking an out-licensing partner for further development. Even if partnered, approval would likely be many years away given the early stage and competitive landscape.

ARV-806 Updated Nov 5

What to watch

The next catalyst for ARV-806 is the Phase 1 monotherapy dose escalation data readout, which was previously guided for the second half of 2026 but was removed from the milestone schedule in the Q3 2026 earnings call (Nov 3, 2026). If data are released, positive results could attract a licensing partner; negative or underwhelming data would likely make out-licensing difficult and confirm the asset's diminished value within Arvinas. The stock already trades near its 52-week low, reflecting this de-prioritization.

Bull case
  • ARV-806 demonstrated sub-nanomolar potency for degrading KRAS G12D and >25-fold greater anti-proliferative potency versus inhibitors and another clinical-stage degrader in preclinical studies (AACR-NCI-EORTC Oct 2025).
  • KRAS G12D is the most common KRAS mutation and a high-value target in pancreatic, colorectal, and lung cancers with no approved therapies yet, representing a large unmet need.
  • Arvinas has a strong PROTAC platform validated by the FDA approval of VEPPANU (vepdegestrant), the first approved PROTAC drug.
Bear case
  • Arvinas removed ARV-806 from its corporate pipeline chart and milestone schedule in the Q3 2026 earnings call (Nov 3, 2026), signaling internal de-prioritization. The CEO highlighted BCL6, polyQ-AR, and HPK1 programs instead.
  • The company plans to out-license any further ARV-806 development beyond Phase 1 dose escalation, meaning future value depends on finding a partner, not internal execution.
  • Astellas' ASP3082 (setidegrasib), a competing KRAS G12D degrader, has already advanced to Phase 3 in NSCLC and pancreatic cancer, putting ARV-806 significantly behind.

Other drugs in filings and trials

no drug report yet
  • VEPPANU Last: Approval · Aug 4, 2026
  • vepdegestrant Last: Fast Track · Jun 5, 2026

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Aug 4, 2026VEPPANUApproval+4.2%+11.5%
Jun 5, 2026vepdegestrantFast Track−7.6%−2.1%
Jun 5, 2026vepdegestrantNDA filed−7.6%−2.1%
Jun 5, 2026vepdegestrantPDUFA decision−7.6%−2.1%
May 12, 2026VEPPANUApproval+2.2%−11.5%
May 1, 2026VEPPANUApproval+8.9%+2.1%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
VepdegestrantA Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerPhase 2Completed · results219Sep 13, 2024